FDA approves generic versions of Lamisil

Share this article:

The FDA today approved the first generic versions of Novartis' Lamisil (terbinafine hydrochloride) tablets, used to treat nail fungus infection (onychomycosis).

The agency approved applications from multiple generic drug manufacturers for terbinafine hydrochloride tablets in 250-milligram formulations. Those generic manufacturers include: Amneal Pharmaceuticals, Apotex, Aurobindo Pharma USA, Dr. Reddy's Laboratories, Gedeon Richter USA, Genpharm, Glenmark Pharmaceuticals, InvaGen Pharmaceuticals, Mylan Pharmaceuticals, Orgenus Pharma, Roxane Laboratories, Teva Pharmaceuticals USA, Watson Laboratories and Wockhardt USA. 

Patent exclusivity for Lamisil expired on June 30.

Lamisil tablets are the 57th-best selling brand-name prescription drug in the US, the FDA said.  

In addition to terbinafine tablets, FDA also approved an application for a generic version of OTC Lamisil cream (terbinafine hydrochloride,1%) to treat athlete’s foot. The cream is manufactured by Taro Pharmaceuticals USA.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.